Interleukin-10 a prognostic factor in treatment with autologous melanoma vaccine
Monday, June 7, 2010 - 11:20
in Health & Medicine
(PHILADELPHIA) Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago.